IHE - iShares U.S. Pharmaceuticals ETF
| Assets | $355.40M |
| NAV | $177.70 |
| Expense Ratio | 0.42% |
| PE Ratio | 24.32 |
| Beta (5Y) | 0.89 |
| Dividend (ttm) | $2.18 |
| Dividend Yield | 1.23% |
| Ex-Dividend Date | Mar 25, 2021 |
| 1-Year Return | - |
| Trading Day | April 16 |
| Last Price | $179.05 |
| Previous Close | $177.80 |
| Change ($) | 1.25 |
| Change (%) | 0.70% |
| Day's Open | 178.89 |
| Day's Range | 178.06 - 179.28 |
| Day's Volume | 3,233 |
| 52-Week Range | 144.25 - 187.42 |
Fund Description
The investment seeks to track the investment results of the Dow Jones U.S. Select Pharmaceuticals Index. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index measures the performance of the pharmaceuticals sector of the U.S. equity market. The underlying index includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The fund is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date May 1, 2006 |
| Exchange NYSEARCA | Ticker Symbol IHE |
| Index Tracked Dow Jones U.S. Select Pharmaceuticals Index | |
Top 10 Holdings
77.50% of assets| Name | Symbol | Weight |
|---|---|---|
| Johnson & Johnson | JNJ | 23.29% |
| Pfizer | PFE | 17.60% |
| Merck | MRK | 5.64% |
| Zoetis | ZTS | 4.73% |
| Catalent | CTLT | 4.67% |
| Bristol-Myers Squibb | BMY | 4.61% |
| Horizon Therapeutics | HZNP | 4.50% |
| Viatris | VTRS | 4.31% |
| Elanco Animal Health | ELAN | 4.12% |
| Eli Lilly | LLY | 4.02% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 25, 2021 | $0.635 | Mar 31, 2021 |
| Dec 14, 2020 | $0.526 | Dec 18, 2020 |
| Sep 23, 2020 | $0.709 | Sep 29, 2020 |
| Jun 15, 2020 | $0.314 | Jun 19, 2020 |
| Mar 25, 2020 | $0.587 | Mar 31, 2020 |
| Dec 16, 2019 | $0.515 | Dec 20, 2019 |
Some biotech and pharmaceutical ETFs are gaining on Tuesday despite news that Johnson and Johnson's coronavirus vaccine has been halted in over two dozen states, after the Food and Drug Administration r...
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
The best pharmaceutical ETFs for Q1 2021 are KURE, XPH, and IHE.
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Strong results led to solid trading in pharma ETFs over the past week.
Robust results led to solid trading in pharma ETFs in a month.
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Healthcare stocks and sector-related exchange traded funds found support from a strong start to the earnings season after UnitedHealth Group (NYSE: UNH) and Johnson & Johnson (NYSE: JNJ) provided a much...
Despite robust results, pharma ETFs have been trending downward in a month.
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
Despite such robust results, pharma ETFs have been trending downward in a month.